Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 16/20 | 0.46 |
| ▸ | CTSB | P07858 | 10/20 | 0.46 |
| ▸ | CTSS | P25774 | 10/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ERG | P11308 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4699575 | 0.83 | CTSK (0.51) | CTSKCTSBCTSSBACE1CTSL | |
| SCHEMBL4699578 | 0.83 | CTSK (0.51) | CTSKCTSBCTSSBACE1CTSL | |
| SCHEMBL4699007 | 0.82 | CTSK (0.48) | CTSKCTSBCTSSCYP3A4ERG | |
| SCHEMBL4704928 | 0.80 | CTSK (0.49) | CTSKCTSBCTSSBACE1CTSL | |
| SCHEMBL4701310 | 0.80 | CTSK (0.43) | CTSKCTSBCTSSCYP3A4ERG | |
| SCHEMBL4701671 | 0.79 | CTSK (0.50) | CTSKCTSBCTSSCTSL | |
| SCHEMBL4699607 | 0.77 | CTSK (0.45) | CTSKCTSBCTSSBACE1 | |
| SCHEMBL4698500 | 0.75 | CTSK (0.43) | CTSKCTSBCTSSBACE1CTSL | |
| SCHEMBL4701895 | 0.74 | CTSK (0.53) | CTSKCTSBCTSSBACE1CTSL | |
| SCHEMBL4700257 | 0.74 | CTSK (0.43) | CTSKCTSBCTSSBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372655-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-10-01 | — | — | EP | claimed |
| US-7012075-B2 | Cathepsin cysteine protease inhibitors | MERCK & CO., INC. (US) | 2006-03-14 | — | — | US | claimed |
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2004-10-07 | — | — | US | claimed |
| EP-1372655-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-10-01 | — | — | EP | disclosed |
| US-7012075-B2 | Cathepsin cysteine protease inhibitors | MERCK & CO., INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSZ | CTSK 4/4885CTSB 1/4885CTSS 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.